Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2005-02-18 Director's Dealing
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Mitteilung uber Geschafte von Fuhrungspersonen nach 15a WpHG
Director's Dealing Classification · 100% confidence The document text explicitly contains the header "Directors’ Dealings" and the German equivalent "Mitteilung über Geschäfte von Führungspersonen nach §15a WpHG" (Notification of transactions by persons discharging managerial responsibilities). It details a 'Verkauf' (Sale) transaction by a 'Geschäftsführendes Organ' (Executive Body member) concerning MorphoSys-Aktie (MorphoSys shares). This directly corresponds to the definition of Director's Dealing.
2005-02-18 German
Mitteilung uber Geschafte von Fuhrungspersonen nach 15a WpHG
Director's Dealing Classification · 100% confidence The document text explicitly contains the header "Directors’ Dealings" and the German equivalent "Mitteilung über Geschäfte von Führungspersonen nach §15a WpHG". It details a 'Verkauf' (Sale) transaction by a 'Geschäftsführendes Organ' (Executive Body/Director) involving a specific number of shares and price. This directly corresponds to the definition of Director's Dealing.
2005-02-18 German
Mitteilung uber Geschafte von Fuhrungspersonen nach 15a WpHG
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the German equivalent 'Mitteilung über Geschäfte von Führungspersonen nach §15a WpHG' (Notification of transactions by persons discharging managerial responsibilities). It details a transaction (conversion of a convertible bond) by a member of the management board ('Funktion: Geschäftsführendes Organ') of MorphoSys AG. This directly corresponds to the definition of Director's Dealing.
2005-02-18 German
Mitteilung uber Geschafte von Fuhrungspersonen nach 15a WpHG
Director's Dealing Classification · 100% confidence The document text explicitly contains the header "Directors’ Dealings" and the German equivalent "Mitteilung über Geschäfte von Führungspersonen nach §15a WpHG" (Notification of transactions by persons discharging managerial responsibilities). It details a transaction (Verkauf/Sale) involving an executive's spouse ('Ehegatte') in the company's stock (MorphoSys-Aktie). This directly corresponds to the definition of Director's Dealing.
2005-02-18 German
MorphoSys AG: MorphoSys Expands Collaboration With Centocor
M&A Activity Classification · 99% confidence The document is an 'Ad hoc announcement' dated December 23, 2004, detailing the expansion of a collaboration agreement between MorphoSys AG and Centocor Inc. This type of announcement, which reports on a significant business development (collaboration extension, financial terms undisclosed), is a general corporate disclosure. It does not fit the specific criteria for an Annual Report (10-K), Earnings Release (ER), Interim Report (IR), or a specific shareholder action like DIV or DVA. Since it is a material, non-standard announcement that doesn't fit the other specific categories (like M&A, Capital Change, or Director Dealing), the most appropriate general classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory disclosures not covered elsewhere, especially those issued under specific regulatory requirements like §15 WpHG.
2004-12-23 English
MorphoSys Announces Extension of Strategic Partnership with Schering AG
M&A Activity Classification · 99% confidence The document is a 'Corporate-news announcement' dated December 20, 2004, detailing the extension of a strategic partnership between MorphoSys AG and Schering AG regarding antibody therapeutics. It discusses business developments, collaboration terms, and future expectations. This type of announcement, which is a general corporate update or press release about a business event (partnership extension, not a financial filing like 10-K or ER), fits best under the general regulatory announcement category, as it does not specifically match AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. Since it is a formal news release sent via DGAP (a common German regulatory news distribution service), and it doesn't fit the specific financial or governance categories, the most appropriate fallback is Regulatory Filings (RNS). The document length (5374 chars) is substantial enough that it is the primary content, not just an announcement of a report.
2004-12-20 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.